Repository logo
 

Three-dimensional model of glioblastoma by co-culturing tumor stem cells with human brain organoids.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

Emerging three-dimensional (3D) cultures of glioblastoma are becoming powerful models to study glioblastoma stem cell behavior and the impact of cell-cell and cell-microenvironment interactions on tumor growth and invasion. Here we describe a method for culturing human glioblastoma stem cells (GSCs) in 3D by co-culturing them with pluripotent stem cell-derived brain organoids. This requires multiple coordinated steps, including the generation of cerebral organoids, and the growth and fluorescence tagging of GSCs. We highlight how to recognize optimal organoid generation and how to efficiently mark GSCs, before describing optimized co-culture conditions. We show that GSCs can efficiently integrate into brain organoids and maintain a significant degree of cell fate heterogeneity, paving the way for the analysis of GSC fate behavior and lineage progression. These results establish the 3D culture system as a viable and versatile GBM model for investigating tumor cell biology and GSC heterogeneity.This article has an associated First Person interview with the first author of the paper.

Description

Journal Title

Biol Open

Conference Name

Journal ISSN

2046-6390
2046-6390

Volume Title

10

Publisher

The Company of Biologists

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)
Sponsorship
Wellcome Trust (098357/Z/12/Z)
Cancer Research UK (A25636)
Royal Society (RP/R1/180165)
Medical Research Council (MC_PC_17230)
Cancer Research UK (25636)
R.A. is supported by Rita Levi Montalcini funding from MIUR (Italian Ministry of Education, University and Research) and from the Society for Developmental Biology (SDB) Innovation Award. B.D.S. is supported by the Royal Society E.P. Abraham Research Professorship (RP\R1\180165) and Wellcome Trust (098357/Z/12/Z). A.P is supported by Cancer Research UK Programme Grant RG91505 and core support from the Wellcome Trust and the MRC Cambridge Stem Cell Institute.